These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11005932)

  • 1. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
    McGuire DK; Newby LK
    J Thromb Thrombolysis; 2000 Oct; 10(2):111-9. PubMed ID: 11005932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
    Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
    Lancet; 2000 Jan; 355(9201):337-45. PubMed ID: 10665552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
    Chew DP; Bhatt DL; Sapp S; Topol EJ
    Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
    Chew DP; Bhatt DL
    Curr Cardiol Rep; 2001 Jan; 3(1):63-71. PubMed ID: 11139801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral platelet glycoprotein IIb/IIIa inhibition.
    Newby LK; McGuire DK
    Curr Cardiol Rep; 2000 Sep; 2(5):372-7. PubMed ID: 10980903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists in the clinic.
    Sy SK; Levenstadt AL
    Am J Cardiovasc Drugs; 2004; 4(1):1-10. PubMed ID: 14967061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
    Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
    Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
    Van de Werf F
    Thromb Haemost; 1997 Jul; 78(1):210-3. PubMed ID: 9198155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
    Newby LK; Califf RM; White HD; Harrington RA; Van de Werf F; Granger CB; Simes RJ; Hasselblad V; Armstrong PW
    Am J Med; 2002 Jun; 112(8):647-58. PubMed ID: 12034415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early clinical results with the new oral glycoprotein IIb/IIIa agents.
    Teirstein PS
    Am J Cardiol; 1999 May; 83(9A):12E-15E. PubMed ID: 10357576
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
    Ault KA; Cannon CP; Mitchell J; McCahan J; Tracy RP; Novotny WF; Reimann JD; Braunwald E
    J Am Coll Cardiol; 1999 Mar; 33(3):634-9. PubMed ID: 10080462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
    Liu F; Craft RM; Morris SA; Carroll RC
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.
    Catella-Lawson F; Kapoor S; Moretti D; De Marco S; Vigilante GJ; Cucchiara AJ; Ramsey KE; Combe S; Rocca B; Theroux P; FitzGerald GA;
    Am J Cardiol; 2001 Aug; 88(3):236-42. PubMed ID: 11472700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.